AP NEWS

Inivata to Present New Clinical Data on the Utility of the InVision® Liquid Biopsy Platform in Advanced Non-Small Cell Lung Cancer (NSCLC) at WCLC 2018

September 10, 2018

Inivata to Present New Clinical Data on the Utility of the InVision® Liquid Biopsy Platform in Advanced Non-Small Cell Lung Cancer (NSCLC) at WCLC 2018 Oral presentations and posters to feature Inivata’s InVisionFirst™ -Lung and the applications of liquid biopsy in Advanced Non-Small Cell Lung Cancer

Research Triangle Park, NC and Cambridge, UK, September 10, 2018 -- Inivata, a leader in liquid biopsy announces that the Company and its world-leading collaborators will showcase cutting-edge data in two mini oral presentations and six posters at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) 23 - 26 September in Toronto. The details are as follows:

Presentation: Feasibility, clinical relevance of ALK/ROS1 fusion variant detection by liquid biopsy in advanced non-small cell lung cancer (MA16.09)Date and time: September 25, 13.30-15.00 Location: Room 203BDFor the list of authors, click here

Presentation: Prospective clinical validation of the InVisionFirst™ ctDNA assay for molecular profiling of patients with advanced NSCLC (MA16.02)Date and time: September 25, 13.30-15.00Location: Room 203BDFor the list of authors, click here

Poster: Multicentre phase II trial of first-line afatinib in patients with suspected/confirmed EGFR mutant NSCLC: ctDNA and long-term efficacy (P1.13-17)Date and time: September 24, 9.45-10.30 and 16.45-18.00Location: Exhibition HallFor the list of authors, click here

Poster: Circulating tumor DNA analysis for predicting response to osimertinib and disease progression in EGFR-mutant non-small-cell lung cancer (NSCLC) (P1.01-46)Date and time: September 24, 9.45-10.30 and 16.45-18.00Location: Exhibition HallFor the list of authors, click here

Poster: Clinical relevance of ALK/ROS1 resistance mutations and other acquired mutations detected by liquid biopsy in advanced NSCLC patients (P1.01-67)Date and time: September 24, 9.45-10.30 and 16.45-18.00Location: Exhibition HallFor the list of authors, click here

Poster: Validation of InVisionFirst ctDNA NGS profiling via ddPCR testing in patients with Non-Small cell lung cancer (NSCLC) (P2.01-78)Date and time: September 25, 9.45-10.30 and 16.45-18.00Location: Exhibition HallFor the list of authors, click here

Poster: Prospective efficacy of osimertinib in circulating tumour DNA (ctDNA) T790M-mutant NSCLC patients (P2.13-24)Date and time: September 25, 9.45-10.30 and 16.45-18.00Location: Exhibition HallFor the list of authors, click here

Poster: Early plasma ctDNA response anticipates clinical response to first-line immunotherapy in advanced NSCLC (P3.04-02)Date and time: September 26, 9.45-10.30 and 12.00-13.30Location: Exhibition HallFor the list of authors, click here

About InivataInivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst™-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

Media Contacts:

Consilium Strategic Communications Chris Gardner/Laura Thornton/Sarah Wilson inivata@consilium-comms.com +44 (0)20 3709 5700

Karen Chandler-Smith karen.chandler-smith@inivata.com +44 (0)7900 430235

AP RADIO
Update hourly